EGFR and non-small cell lung carcinoma: As the number of predictive gene biomarkers and targeted therapies for NSCLC continues to grow, there is also increasing evidence demonstrating the clinical utility and cost-effectiveness of next-generation sequencing (NGS) multiplex panels, compared to sequential testing of individual gene targets (e.g., EGFR, ALK, BRAF, etc.).